RESOLUTION AUTHORIZING ACCEPTANCE OF A GRANT AWARD
FROM INTERMUNE, INC. TO CONDUCT A CLINICAL STUDY TO
ASSESS THE SAFETY AND EFFECTIVENESS OF TWO DOSE LEVELS OF
INTERFERON ALFACON-1 (INFERGEN®, CIFN) PLUS RIBAVIRIN
ADMINISTERED FOR 48 WKS VS. NO TREATMENT IN HEPATITIS C
INFECTED PATIENTS WHO ARE NON-RESPONDERS TO PREVIOUS
PEGYLATED INTERFERON ALFA PLUS RIBAVIRIN THERAPY
|